(Q46473101)

22 December 2017

title

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture (English)

1 reference

22 December 2017

1 reference

J A Kanis

1

1 reference

22 December 2017

I P Barton

series ordinal

2

1 reference

22 December 2017

O Johnell

series ordinal

3

1 reference

22 December 2017

language of work or name

English

0 references

publication date

23 July 2004

1 reference

22 December 2017

Osteoporosis International

published in

1 reference

22 December 2017

volume

16

1 reference

22 December 2017

page(s)

475-482

1 reference

22 December 2017

issue

5

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/s00198-004-1698-y

exact match

0 references

cites work

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-004-1698-Y

Bone mineral density thresholds for pharmacological intervention to prevent fractures

21 January 2018

1 reference

12 December 2020

Design of the Fracture Intervention Trial

1 reference

12 December 2020

What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis?

1 reference

12 December 2020

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

1 reference

12 December 2020

Guidelines for diagnosis and management of osteoporosis

1 reference

12 December 2020

Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Assessing the risk of vertebral osteoporosis.

1 reference

12 December 2020

Diagnosis of osteoporosis and assessment of fracture risk

1 reference

12 December 2020

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

1 reference

12 December 2020

An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation

1 reference

12 December 2020

The diagnosis of osteoporosis

1 reference

12 December 2020

Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study

1 reference

12 December 2020

Consensus development conference: prophylaxis and treatment of osteoporosis

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment

1 reference

12 December 2020

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

1 reference

12 December 2020

Position statement : executive summary. The Writing Group for the International Society for Clinical Densitometry (ISCD) Position Development Conference

1 reference

12 December 2020

Vitamin D3 and calcium to prevent hip fractures in elderly women

1 reference

12 December 2020

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

1 reference

12 December 2020

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

1 reference

12 December 2020

Updated data on proximal femur bone mineral levels of US adults

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

10.1007/S00198-004-1698-Y

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

15875093

1 reference

22 December 2017